Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-03-17 Audit Report / Informat…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, revenue, profit), and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a formal notification of the audit report's completion and submission to the regulator, rather than the full annual report document itself. Under the provided definitions, this fits the 'Report Publication Announcement' (RPA) category as it announces the availability/submission of the audit report. FY 2025
2026-03-17 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 16th fiscal year (2025) of EuBiologics Co., Ltd. It contains comprehensive financial statements, management discussion and analysis, business operations, governance, and shareholding information. This is the standard Korean regulatory filing equivalent to a 10-K in the US market. FY 2025
2026-03-17 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 95% confidence The document is a 'Correction Report' (정정신고) regarding a 'Notice of General Meeting of Shareholders' (주주총회소집공고). It provides detailed financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement) for the 16th and 15th fiscal years, specifically noting that the corrections were made to reflect the external auditor's audit results. Since this document contains the full financial statements and audit-related adjustments for the annual period, it functions as an Annual Report or a comprehensive financial disclosure associated with the AGM. Given the structure and content, it is classified as an Annual Report (10-K).
2026-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for the 16th Annual General Meeting of EU Biologics. It contains the meeting agenda, details on voting procedures, board activity reports, and financial statements for shareholder approval. This document is a standard proxy statement/notice package provided to shareholders to inform them of the upcoming meeting and solicit their participation/votes. In the context of the provided categories, this fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) for UBIOLOGICS. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, and proxy solicitation details. While it contains financial information, the primary regulatory purpose of this specific filing is to solicit proxies from shareholders for the AGM, which falls under the Proxy Solicitation & Information Statement category.
2026-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Eubiologics. It details the date, location, agenda items (such as financial statement approval, director/auditor appointments, and articles of incorporation changes), and specific candidate details. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.